An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer
Abstract Background Immuno-radiotherapy may improve outcomes for patients with advanced solid tumors, although optimized combination modalities remain unclear. Here, we report the colorectal (CRC) cohort analysis from the SABR-PDL1 trial that evaluated the PD-L1 inhibitor atezolizumab in combination...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2024-03-01
|
Series: | Molecular Cancer |
Online Access: | https://doi.org/10.1186/s12943-024-01970-8 |